Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Lana_Del_Rey
|
| gptkbp:appointed_by |
injection
smoking snorting |
| gptkbp:can_lead_to |
psychological dependence
physical dependence |
| gptkbp:caused_by |
overdose
|
| gptkbp:developed_by |
morphine
|
| gptkbp:has_impact_on |
central nervous system
|
| https://www.w3.org/2000/01/rdf-schema#label |
Heroin
|
| gptkbp:is_a |
narcotic
|
| gptkbp:is_associated_with |
gptkb:drug
gptkb:social_stigma hepatitis crime rates family issues HIV transmission youth issues social services involvement |
| gptkbp:is_available_on |
a prescription medication in some countries
|
| gptkbp:is_considered |
a complex issue
a public health issue a chronic disease a Schedule I drug in the US a gateway drug |
| gptkbp:is_known_for |
pain relief
euphoria sedation rapid onset of effects short duration of effects |
| gptkbp:is_linked_to |
gptkb:Police_Department
public policy debates mental health disorders homelessness community health issues economic costs overdose deaths |
| gptkbp:is_part_of |
substance use disorder
drug culture addiction treatment programs drug education programs drug rehabilitation programs the opioid epidemic |
| gptkbp:is_related_to |
tolerance
withdrawal symptoms |
| gptkbp:is_subject_to |
gptkb:municipality
|
| gptkbp:is_used_by |
recreational users
|
| gptkbp:is_used_for |
pain relief
|
| gptkbp:is_used_in |
gptkb:Research_Institute
clinical trials pain management harm reduction strategies addiction recovery support opioid substitution therapy pain management protocols |
| gptkbp:legal_issue |
most countries
|
| gptkbp:metabolism |
gptkb:6-monoacetylmorphine
morphine |
| gptkbp:produced_by |
gptkb:chemical_compound
|